论文部分内容阅读
目的:探讨沙利度胺对原发性肝癌(HCC)介入后血管内皮生长因子(VEGF)及生存质量的影响。方法:将2014年1月至2016年1月期间我院收治的拟行肝动脉栓塞化疗(TACE)的HCC患者60例按照随机数字表法分为A、B两组,各30例。A组患者采用TACE+沙利度胺治疗,每晚200 mg,口服一个月;B组患者单行TACE治疗。分别于治疗前、治疗后3周检测两组患者的VEGF水平,于治疗前、治疗后1个月应用生存质量评分量表(QOL)评价患者生存质量,并比较两组患者治疗前后的体重及治疗过程中的不良反应。结果:治疗前两组患者血清VEGF水平差异无统计学意义(P>0.05)。治疗后两组患者VEGF水平均较治疗前升高,其中A组患者治疗后VEGF水平显著低于B组患者(P<0.01)。治疗前两组患者QOL分数和体重比较差异无统计学意义(P>0.05)。而治疗后两组患者的QOL分数较治疗前均有所降低,但A组患者的QOL分数显著高于B组患者(P<0.05),而两组患者治疗后的体重无统计学差异(P>0.05)。A组30例患者中有1例(3.33%)患者因严重嗜睡、2例(6.67%)患者因严重口腔干燥而终止口服沙利度胺,其余27例患者均能耐受。结论:沙利度胺联合TACE方法治疗HCC可降低VEGF水平和改善癌症患者的生存质量,值得在临床上推广使用。
Objective: To investigate the effect of thalidomide on vascular endothelial growth factor (VEGF) and quality of life in patients with primary hepatocellular carcinoma (HCC) after interventional therapy. Methods: Sixty patients with HCC undergoing transcatheter arterial chemoembolization (TACE) admitted to our hospital from January 2014 to January 2016 were divided into two groups (A and B), 30 cases in each group according to the random number table. Group A patients treated with TACE + thalidomide, 200 mg night, oral for one month; patients in group B TACE alone. The levels of VEGF in both groups were measured before treatment and 3 weeks after treatment. The quality of life was evaluated by QOL before treatment and one month after treatment. The body weight, Adverse reactions during treatment. Results: There was no significant difference in serum VEGF levels between the two groups before treatment (P> 0.05). After treatment, the levels of VEGF in both groups were higher than those before treatment, and the level of VEGF in group A was significantly lower than that in group B after treatment (P <0.01). There was no significant difference in QOL scores and body weight between the two groups before treatment (P> 0.05). After treatment, the QOL scores of the two groups were lower than those before treatment, but the QOL scores of patients in group A were significantly higher than those in group B (P <0.05), while there was no significant difference between the two groups > 0.05). One patient (30%) in group A suffered from severe drowsiness in one patient (3.33%), and two patients (6.67%) terminated oral thalidomide in severe oral cavity. The other 27 patients were tolerated. Conclusion: Thalidomide combined with TACE in the treatment of HCC can reduce the level of VEGF and improve the quality of life of patients with cancer, which is worth popularizing in clinic.